Samsung Biologics’ Cell Line Development Group has implemented a novel high-throughput screening method for analyzing a molecule’s sialic acid profile by measuring its binding affinity with lectin. For this assay, lectins, sugar-binding proteins highly specific to their associated sugar moieties, are leveraged to improve specificity.
An early-stage assessment tool can mitigate development risk and help minimize scale-up risk by facilitating the identification of potential issues — as well as informing the development of strategies to address them — before those issues become major problems. This process also is conducive to developing a more effective drug product.
As biopharmaceuticals become more prevalent, the need for specialized manufacturing techniques, the criticality of product consistency, and the importance of molecule characterization will render high-quality CMC services even more indispensable. Tailored CMC services also can lead to shorter global licensing timelines and minimize variability in globally registered product details.
Samsung Biologics is a fully integrated, end-to-end CDMO service provider offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish for biologics. Our facilities are cGMP compliant, with bioreactor sizes ranging from small to large scale, enabling us to better serve the various needs of our clients and to meet growing biomanufacturing demands.
